Physician profile
Suzanne Cerrone
NPI 1083039192
$1,695.74
in general payments reported to CMS, 2019-2025
16 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $588 · 2022: $886 · 2023: $20.11 · 2024: $55.46 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.02 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $358.45 | 2021-2023 | |
| Janssen Biotech, INC. | $192.07 | 2021-2022 | |
| Galderma Laboratories, L.P. | $141.43 | 2022-2025 | |
| Ucb, INC. | $139.20 | 2021-2022 | |
| Leo Pharma INC. | $117.60 | 2021-2022 | |
| Incyte Corporation | $90.45 | 2022 | |
| Revance Therapeutics, INC. | $62.51 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $36.25 | 2022 | |
| Journey Medical Corporation | $27.45 | 2022 | |
| Almirall LLC | $22.22 | 2021 | |
| Genzyme Corporation | $22.12 | 2021 | |
| Amgen INC. | $21.31 | 2022 | |
| Vyne Pharmaceuticals INC. | $18.55 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.27 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $16.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Cerrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.